Implications of the growing burden of diabetes for premature cardiovascular disease mortality and the attainment of the Sustainable Development Goal target 3.4.

Cardiovascular diseases (CVD) diabetes mellitus mortality premature

Journal

Cardiovascular diagnosis and therapy
ISSN: 2223-3652
Titre abrégé: Cardiovasc Diagn Ther
Pays: China
ID NLM: 101601613

Informations de publication

Date de publication:
Apr 2019
Historique:
entrez: 31 5 2019
pubmed: 31 5 2019
medline: 31 5 2019
Statut: ppublish

Résumé

Non-communicable diseases (NCDs) are a major cause of deaths globally, and cardiovascular disease (CVD) is the leading cause of these deaths. 42% of NCD deaths are premature (occurring before the age of 70 years). As part of the United Nations 3rd Sustainable Development Goal (SDG) on health and wellbeing, target 3.4 is to reduce premature mortality from NCDs by one third between 2015 and 2030. This target adds to the World Health Organization (WHO) target of reducing premature deaths from NCDs by 25% between 2010 and 2025. As diabetes is a major risk factor for CVD, it is important to account for the trends in diabetes when considering premature CVD mortality. We aimed to describe the global trends in diabetes prevalence and mortality, critically review the literature on the estimated attainability of the WHO and SDG targets, and determine if and how these studies accounted for trends in diabetes. Worldwide, the prevalence of diabetes is rising, with an estimated 9.0% global prevalence in adults aged 20-69 by 2030, and low- and middle-income countries (LMICs) having the largest increase of the burden in absolute numbers and age-standardized prevalence. There is a lack of data from most LMICs on the excess CVD mortality associated with diabetes and therefore no consensus on the global risk of CVD mortality in people with diabetes. Where data do exist, there are discrepancies between studies on the direction of mortality trends from diabetes over time. We reviewed 12 studies that estimated the attainability of the WHO or SDG targets for premature NCD mortality. Seven of these considered the potential impacts of achieving the 2025 WHO risk factor targets. Six studies modelled the impact of current trends in risk factors, including diabetes, continuing toward the target dates. Four studies compared this 'business as usual' model with the attainment of the risk factor targets for the world as whole and individual regions, 2 studies for NCD mortality overall, and 2 specifically for CVD mortality. On the impact of diabetes with regards to attainment of the WHO or SDG targets for premature CVD mortality, the overall results were inconclusive. Some concluded that none of the countries or regions considered would meet the targets, and others predicted that in some areas, the targets would be met. Examining the potential impact of trends in diabetes on future CVD mortality rates in LMICs is limited by a relative lack of high quality studies, including on the age specific excess mortality associated with diabetes. Filling these data gaps will enable better estimates of the potential impacts on future CVD mortality of the rapidly increasing prevalence of diabetes in LMICs and help to better inform health policy and the attainment of SDG target 3.4.

Identifiants

pubmed: 31143635
doi: 10.21037/cdt.2018.09.04
pii: cdt-09-02-140
pmc: PMC6511678
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

140-149

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Déclaration de conflit d'intérêts

Conflicts of Interest: The authors have no conflicts of interest to declare.

Références

Diabetes Care. 2005 Sep;28(9):2130-5
pubmed: 16123478
N Engl J Med. 2007 Jun 7;356(23):2388-98
pubmed: 17554120
Ann Intern Med. 2007 Aug 7;147(3):149-55
pubmed: 17576993
Eur Heart J. 2009 May;30(9):1046-56
pubmed: 19141562
BMC Public Health. 2009 Jan 22;9:30
pubmed: 19159492
PLoS One. 2010 Nov 12;5(11):e13957
pubmed: 21103050
Eur J Prev Cardiol. 2014 Jul;21(7):829-39
pubmed: 23180867
PLoS One. 2013 May 03;8(5):e63202
pubmed: 23658808
Diabetologia. 2013 Dec;56(12):2601-8
pubmed: 24114114
BMC Public Health. 2013 Dec 05;13:1135
pubmed: 24308515
J Clin Endocrinol Metab. 2014 Apr;99(4):E642-6
pubmed: 24483155
Lancet. 2014 Aug 2;384(9941):427-37
pubmed: 24797573
JAMA Intern Med. 2014 Jul;174(7):1187-8
pubmed: 24841330
Diabetes Care. 2014 Sep;37(9):2579-86
pubmed: 24947787
Lancet. 2015 Jan 17;385(9964):239-52
pubmed: 25242039
BMC Med. 2015 Mar 30;13:65
pubmed: 25889300
Circulation. 2015 Sep 29;132(13):1270-82
pubmed: 26408271
Lancet Glob Health. 2015 Dec;3(12):e746-57
pubmed: 26497599
PLoS One. 2015 Oct 29;10(10):e0141685
pubmed: 26512989
Lancet. 2016 Apr 9;387(10027):1513-30
pubmed: 27061677
Circulation. 2016 Jun 7;133(23):e674-90
pubmed: 27162236
Diabetologia. 2016 Oct;59(10):2106-13
pubmed: 27465219
Lancet Glob Health. 2016 Oct;4(10):e714-25
pubmed: 27596038
BMJ Open. 2017 Apr 4;7(4):e012805
pubmed: 28377390
Diabetes Obes Metab. 2018 Jan;20(1):85-93
pubmed: 28640432
BMC Med. 2017 Jul 11;15(1):132
pubmed: 28693510
Lancet. 2017 Sep 16;390(10100):1423-1459
pubmed: 28916366
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Heart Asia. 2017 Aug 7;9(2):e010905
pubmed: 29467836

Auteurs

Constance Wou (C)

MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.

Nigel Unwin (N)

MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.

Yadi Huang (Y)

International Diabetes Federation, Brussels, Belgium.

Gojka Roglic (G)

Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention, World Health Organization, Geneva, Switzerland.

Classifications MeSH